Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 10, 2022 at 04:03 pm EDT
Share
Spero Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 1.99 million compared to USD 5.15 million a year ago. Net loss was USD 28.68 million compared to USD 18.57 million a year ago. Basic loss per share from continuing operations was USD 0.87 compared to USD 0.63 a year ago. Diluted loss per share from continuing operations was USD 0.87 compared to USD 0.63 a year ago.
For the six months, revenue was USD 4.06 million compared to USD 12.45 million a year ago. Net loss was USD 61.51 million compared to USD 38 million a year ago. Basic loss per share from continuing operations was USD 1.88 compared to USD 1.29 a year ago. Diluted loss per share from continuing operations was USD 1.88 compared to USD 1.29 a year ago.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Its partnership-directed programs consist of tebipenem HBr and SPR206. The tebipenem HBr is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. SPR206 is a direct acting intravenous (IV)-administered product candidate being developed as an option to treat MDR Gram-negative bacterial infections in the hospital setting.
SPERO THERAPEUTICS, INC. 
